Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06622655
Recruiting Not applicable

Clinical Improvement Due to the Home Use of Agilik in Children With Cerebral Palsy

NCT06622655 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2024-10-29
Last updated
2026-06-26

Condition(s) studied

Cerebral Palsy (CP)

Investigational drug(s) / intervention(s)

Powered orthosis

Powered orthosis: Home rehabilitation (2 months, 30 minutes/day, 5 days/week) during which subjects will practice walking with the device at home.

Study summary

The goal of this clinical trial is to learn if a two month training with the Agilik powered orthosis improves the knee extension or the endurance in pediatric patients with Cerebral palsy and a crouch gait. It will also learn about the safety of Agilik. The main questions it aims to answer are:

Does the Agilik powered orthosis increase the value of the knee extension during walking? What medical problems do participants have when using the Agilik powered orthosis? Researchers will compare a group of patients using the Agilik powered exoskeleton with a group of patients treated with standard therapy.

Participants will:

Use Agilik at home or perform standard therapy for 2 months Visit the clinic at the beginning of the study, after 3 months and after 1 additional month.

Eligibility

Sex
ALL
Min age
5 Years
Max age
17 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of CP and a crouch gait * Provision of signed and dated informed consent form. * Stated willingness to comply with all study procedures and availability for the duration of the study, or alternatively, ability to do so based on parent report and physician observation during history and physical examination. * Body weight between 20 and 125 Kg * Knee flexion retraction assessed in supine position by less than 10°. Hamstring contracture as assessed by straight leg raising test does not limit ability to participate in the study. * Subjects must not have had a tibio-tarsal arthrodesis. In addition, they must have at least 5° of passive dorsi-flexion of the ankle. * Able to walk at least 3 m without stopping, with or without a walking aid. * Able to understand and follow simple directions based on parent report and physician observation during historical and physical examination. * GMFCS level I, II and III * MAS score ≤ 2 Exclusion Criteria: * Any severe neurological, musculoskeletal and/or cardiorespiratory involvement preventing the ability to walk; * A history of uncontrolled seizure in the past year * Severe spasticity * Hip and/or knee flexion contracture of more than 20°

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
IRCCS E. MEDEA - Associazione "La Nostra Famiglia" Bosisio Parini Lecco Recruiting
IRCCS Fondazione Stella Maris Calambrone Pisa Not Yet Recruiting
Fondazione Don Carlo Gnocchi Onlus - IRCCS S. Maria Nascente Milan Italy Recruiting
Fondazione Mondino Pavia Italy Not Yet Recruiting
Fondazione Don Carlo Gnocchi Onlus Roma Italy Recruiting
Fondazione Don Carlo Gnocchi Onlus - Centro S. Maria al Mare Salerno Italy Recruiting

More IRCCS Eugenio Medea trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06622655 on ClinicalTrials.gov ↗ ← All trials in Italy